Hemostemix (CVE:HEM) Reaches New 52-Week Low at $0.05

Hemostemix Inc. (CVE:HEM) shares reached a new 52-week low during mid-day trading on Tuesday . The company traded as low as C$0.05 and last traded at C$0.06, with a volume of 40000 shares changing hands. The stock had previously closed at C$0.06.

Hemostemix Stock Down 8.3 %

The company has a market cap of C$4.94 million, a PE ratio of -1.38 and a beta of 0.55. The business’s 50 day moving average price is C$0.07 and its 200-day moving average price is C$0.08.

Hemostemix Company Profile

Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions. The company develops cell therapy products from the patient's own blood, which is a non-invasive source of therapeutic cells. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia in Canada and the United States.